What question did this study set out to answer?

To evaluate the effectiveness of CD34 selected stem cell boost in patients with poor graft function after allogenic stem cell transplantation.

December 8, 2025BloodOpen Access

CD34 selected stem cell boost provides robust outcomes in patients with poor graft function

View Full Paper

Ask AI

Bookmark

Authors

HCHannah ChoeThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute MKMerle KolkThe Ohio State University MDMichael DaunovUniversity Hospitals of Cleveland

Discussion

Member takes

Implication

Randomised trial shows CD34 selected stem cell boost improves hematological response in patients with poor graft function, suggesting a valuable treatment option.

Key Points

To evaluate the effectiveness of CD34 selected stem cell boost in patients with poor graft function after allogenic stem cell transplantation.
Reviewed outcomes of CD34+ selected stem cell boost in two cohorts (n=28 total)
Cohorts received G-CSF mobilized apheresis products
Analyzed recovery rates and hematological responses post-boost
Overall hematological response rate to the boost was 68%
32% achieved complete hematological response
One-year overall survival rate was 45%

Cite This Study

Choe et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2e9 https://doi.org/10.1182/blood-2025-7790

View Full Paper

Ask AI

Bookmark

Implication

Randomised trial shows CD34 selected stem cell boost improves hematological response in patients with poor graft function, suggesting a valuable treatment option.

CD34 selected stem cell boost provides robust outcomes in patients with poor graft function

Discussion

Member takes

Implication

Key Points

Cite This Study

CD34 selected stem cell boost provides robust outcomes in patients with poor graft function

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider